Sangamo BioSciences | SGMO - Selling And Administration Expenses


Sangamo BioSciences reported $9.64M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 424K 23K Jun/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Amgen USD 1.68B 40M Sep/2026
Bayer EUR 4.02B 53M Sep/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Biogen USD 752M 42.3M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.44M 5K Jun/2026
CSL USD 1.23B 498M Dec/2025
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
Grifols EUR 320.45M 12.65M Dec/2025
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
J&J USD 6.25B 168M Sep/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
Merck USD 2.86B 25M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Omeros USD 11.32M 2.48M Sep/2024
Pfizer USD 3.28B 132M Sep/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.31B 325M Sep/2026
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
Tectonic Therapeutic USD 6.17M 260K Jun/2026
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026